companies

AMLo Biosciences

Founded 2017
Employees 10+
Primary contact
Office 9, The Biosphere
Drayman's Way, Newcastle Helix
NE4 5BX Newcastle upon Tyne
United Kingdom
Links
https://amlo-biosciences.com/
Diseases & Conditions
Sections
A spin-out from Newcastle University, AMLo Biosciences is developing predictive tests for cancers with unmet needs. Its first product is an immunohistochemical test for non-ulcerated, cutaneous melanomas, which can accurately identify those tumors at low risk of recurrence/spread, reducing patient anxiety associated with cancer.
Founded 2017
Employees 10+
Primary contact
Office 9, The Biosphere
Drayman's Way, Newcastle Helix
NE4 5BX Newcastle upon Tyne
United Kingdom
Links
https://amlo-biosciences.com/
Diseases & Conditions
Sections

Funding 💰

Total £2.5M
Last round 🔗 £2.45M
April 21, 2022.
Select investors Ascension, Future Planet Capital, Esperante Ventures, Northstar Ventures

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Big market: Melanoma is one of the cancers targeted by AMLo. It is the 5th most common cancer in the UK and the US, with Australia and New Zealand having the highest rates of melanoma in the world. Globally, there were more than 320,000 new cases of melanoma in 2020 and more than 57,000 deaths from metastatic disease. Other types of cancer the company is targeting are cutaneous squamous cell carcinoma (cSCC) and oropharyngeal squamous cell carcinoma (OPSCC). 🔗
  • Big impact: Improving prognostics in melanoma has the potential to transform standard of care. It will enable those patients with melanomas that are genuinely at low-risk of disease progression to be given reassurance and better-informed follow up care, while those identified to be at-risk of progression will receive timely treatment and standard-of-care follow up. AMLo Biosciences plans to launch its technology globally and make a positive impact on the lives of the 300,000+ people diagnosed worldwide with malignant melanoma every year.
  • Knowledgable founders: AMLo Biosciences has been founded by a team with an internationally acclaimed research track record in the melanoma field through the identification of translational biomarkers, drug discovery, and development, and the building of biotech companies. 🔗

Quotes 💬

“
Already in this relatively short period, the firm has achieved significant milestones including scientific validation and a successful pilot launch in the U.K. We look forward to supporting them during the next stage of their expansion as the company scales up to become a commercial success, with further launch in the U.K. and the U.S.
— Guy Pengelley, portfolio manager at Future Planet Capital 🔗
“
We are extremely excited to back AMLo in their mission to help patients identify their risk of melanoma progression alongside Ascension's Conduit EIS Impact Fund and other noteworthy investors. We are looking forward to the launch of AMBLor later this year which will help identify the likelihood of the spread of melanoma at the earliest moment and potentially improve the lives of many.
— Dr. Ala Alenazi, Investment Associate at Ascension Life Fund 🔗
“
We have worked with AMLo since inception and have been consistently impressed by the quality of the technology and the expertise of the team. This investment gives the company the fuel to accelerate development and bring a valuable prognostic tool to market, meeting a real unmet need. Amlo is a great example of one of the growing number of female led businesses which are coming out of the region's universities.
— Alex Buchan, Investment Director at NorthStar Ventures 🔗
Last update: March 17, 2023